Antonin De Fougerolles News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evox Therapeutics publishes new research identifying potent scaffold proteins

Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.

Nature communicationsAntonin de fougerollesBio developments

Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics s proprietary exosome engineering platform

OXFORD, United Kingdom, Aug. 09, 2023 (GLOBE NEWSWIRE) Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced the publication in Nature Communications of Evox-funded research

United kingdomSimon conway natalieEvox therapeutics ltdTherapeutics ltdNature communicationsAntonin de fougerollesChief executive officer

EVOX THERAPEUTICS LIMITED: Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics s proprietary exosome engineering platform

EVOX THERAPEUTICS LIMITED: Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics s proprietary exosome engineering platform
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSimon conway natalieAntonin de fougerollesChief executive officerAktien sie

Evox Therapeutics reaches gene therapy agreement

Evox Therapeutics reaches gene therapy agreement
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Susmita sahooIcahn school of medicineIcahn schoolNew york based icahn schoolIcahn mount sinaiAntonin de fougerolles

Evox Therapeutics to advance gene therapy for treatment of heart disease

Evox Therapeutics, an exosome therapeutics company, has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, US.

Susmita sahooIcahn mount sinaiAntonin de fougerollesBio developmentsEmerging marketsGene therapy